title: [The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET].
abstract: Recent biotechnological advances allowed the development of a novel class of anti-cancer drugs called monoclonal antibodies (mAb). To illustrate the potential of these new agents, two mAbs used in daily practice (i.e., trastuzumab and cetuximab) and two promising targets (i.e., IGF-1R and c-Met) for which mAbs should be available in a near future are discussed here. Trastuzumab and cetuximab deeply changed treatment strategies for breast, colon, and head and neck cancers. However their efficacy is observed in a fraction of patients only and is often time limited. Thus, current challenges are to better understand the mechanisms of action of mAbs, to identify mechanisms of resistance, to exploit the synergy between mAbs and chemotherapy drugs, and to better select patients with a potential benefit. Resolving these issues should pave the way for tailored treatment according to tumor and patient characteristics.
authors.affiliation: Hôpitaux universitaires de Genève, Centre d'oncologie, rue Gabrielle Perret Gentil, 1211 Genève 14, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Bodmer
authors.forename: Liliane
authors.initials: L
authors.lastname: Goetsch
authors.forename: Laurence
authors.initials: L
authors.lastname: Favet
authors.forename: Christian
authors.initials: C
authors.lastname: Bailly
authors.forename: Nathalie
authors.initials: N
authors.lastname: Corvaia
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Dietrich
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology; D006801:Humans; D005810:Multigene Family; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D018579:Patient Selection; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068818:Cetuximab; D066246:ErbB Receptors; D009363:Neoplasm Proteins; D019859:Proto-Oncogene Proteins c-met; D018719:Erb-b2 Receptor Tyrosine Kinases; D017526:Receptor, IGF Type 1; D000068878:Trastuzumab; C512478:EGFR protein, human; C508053:ERBB2 protein, human